Brown-Elliott Barbara A, Wallace Richard J
The University of Texas Health Science Center at Tyler, Department of Microbiology, Tyler, Texas, USA
The University of Texas Health Science Center at Tyler, Department of Microbiology, Tyler, Texas, USA.
J Clin Microbiol. 2017 Jun;55(6):1747-1754. doi: 10.1128/JCM.00274-17. Epub 2017 Mar 22.
Tedizolid is a new oxazolidinone with improved and intracellular potency against , including multidrug-resistant strains, and some species of nontuberculous mycobacteria (NTM) compared with that of linezolid. Using the current Clinical and Laboratory Standards Institute (CLSI)-recommended method of broth microdilution, susceptibility testing of 170 isolates of rapidly growing mycobacteria showed equivalent or lower (1- to 8-fold) MIC and/or MIC values for tedizolid compared with that for linezolid. The tedizolid MIC values for 81 isolates of subsp. and 12 isolates of subsp. were 8 μg/ml and 4 μg/ml, respectively, compared with linezolid MIC values of 32 μg/ml for both. The MIC values for 20 isolates of were 2 μg/ml for tedizolid and 4 μg/ml for linezolid. Twenty-two isolates of had tedizolid and linezolid MICs of 2 μg/ml and 16 μg/ml, respectively. One hundred forty-two slowly growing NTM, including 7/7 , 7/7 , and 7/11 of other less commonly isolated species, had tedizolid MICs of ≤1 μg/ml and linezolid MICs of ≤4 μg/ml. One hundred isolates of complex and eight isolates had tedizolid MICs of 8 μg/ml and linezolid MICs 32 and 64 μg/ml, respectively. Nine isolates had MICs of 4 μg/ml and 16 μg/ml for tedizolid and linezolid, respectively. These findings demonstrate a greater potency of tedizolid than linezolid against NTM and suggest that an evaluation of tedizolid as a potential treatment agent for infections caused by selected NTM is warranted.
替加环素是一种新型恶唑烷酮类药物，与利奈唑胺相比，其对包括耐多药菌株在内的结核分枝杆菌以及一些非结核分枝杆菌（NTM）具有更高的体外和细胞内活性。采用当前临床和实验室标准协会（CLSI）推荐的肉汤微量稀释法，对170株快速生长分枝杆菌进行药敏试验，结果显示替加环素的最低抑菌浓度（MIC）和/或最低杀菌浓度（MBC）值与利奈唑胺相当或更低（低1至8倍）。81株脓肿分枝杆菌亚种和12株龟分枝杆菌亚种的替加环素MIC值分别为8μg/ml和4μg/ml，而两者的利奈唑胺MIC值均为32μg/ml。20株偶发分枝杆菌的替加环素MIC值为2μg/ml，利奈唑胺为4μg/ml。22株耻垢分枝杆菌的替加环素和利奈唑胺MIC值分别为2μg/ml和16μg/ml。142株缓慢生长的NTM，包括7/7株鸟分枝杆菌、7/7株胞内分枝杆菌以及7/11株其他较少见的菌种，替加环素MIC值≤1μg/ml，利奈唑胺MIC值≤4μg/ml。100株结核分枝杆菌复合群和8株堪萨斯分枝杆菌的替加环素MIC值为8μg/ml，利奈唑胺MIC值分别为32μg/ml和64μg/ml。9株海分枝杆菌的替加环素和利奈唑胺MIC值分别为4μg/ml和16μg/ml。这些结果表明，替加环素对NTM的抗菌活性比利奈唑胺更强，提示有必要评估替加环素作为某些NTM感染潜在治疗药物的可能性。
